Marissa B Savoie1, Alan Paciorek1,2, Li Zhang1,2,3, Erin L Van Blarigan1,2, Nilli Sommovilla1, Donald Abrams1,3, Chloe E Atreya1,3, Emily K Bergsland1,3, Hueylan Chern1,4, Robin K Kelley1,3, Andrew Ko1,3, Angela Laffan1, Ankit Sarin1,4, Madhulika G Varma1,4, Alan P Venook1,3, Katherine Van Loon5,6. 1. UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. 2. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. 3. Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, CA, USA. 4. Department of Colorectal Surgery, University of California, San Francisco, CA, USA. 5. UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA. katherine.vanloon@ucsf.edu. 6. Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, CA, USA. katherine.vanloon@ucsf.edu.
Abstract
PURPOSE: We aimed to described 25-hydroxyvitamin D [25(OH)D] levels in newly diagnosed colorectal cancer (CRC) patients and to re-evaluate levels after chemotherapy. METHODS: Permanent residents of the San Francisco Bay Area with a new CRC diagnosis of any stage were recruited prior to any non-surgical therapy. Serum 25(OH)D levels were measured at time of diagnosis and 6-month follow-up. Supplement use was not restricted. The primary endpoint was the frequency of vitamin D deficiency in patients with newly diagnosed CRC of all stages. The Kruskal-Wallis and Spearman correlation tests were used to evaluate associations of patient characteristics with 25(OH)D levels. RESULTS: Median 25(OH)D level at baseline was 27.0 ng/mL (range 7.2, 59.0); 65% of patients had insufficient levels (25(OH)D < 30 ng/mL) (n = 94). Race, disease stage, multivitamin use, vitamin D supplementation, and county of residence were associated with baseline 25(OH)D levels (P < 0.05). The median change in 25(OH)D from baseline to 6 months was - 0.7 ng/mL [- 19.4, 51.7] for patients treated with chemotherapy (n = 58) and 1.6 ng/mL [- 6.4, 33.2] for patients who did not receive chemotherapy (n = 19) (P = 0.26). For patients who received vitamin D supplementation during chemotherapy, the median 25(OH)D change was 8.3 ng/mL [- 7.6, 51.7] versus - 1.6 [- 19.4, 24.3] for chemotherapy patients who did not take vitamin D supplements (P = 0.02). CONCLUSION: Among patients with a new diagnosis of CRC, most patients were found to have 25(OH)D levels consistent with either deficiency or insufficiency. In the subset of patients who received chemotherapy and took a vitamin D supplement, serum 25(OH)D levels increased, suggesting that vitamin D repletion is a feasible intervention during chemotherapy.
PURPOSE: We aimed to described 25-hydroxyvitamin D [25(OH)D] levels in newly diagnosed colorectal cancer (CRC) patients and to re-evaluate levels after chemotherapy. METHODS: Permanent residents of the San Francisco Bay Area with a new CRC diagnosis of any stage were recruited prior to any non-surgical therapy. Serum 25(OH)D levels were measured at time of diagnosis and 6-month follow-up. Supplement use was not restricted. The primary endpoint was the frequency of vitamin Ddeficiency in patients with newly diagnosed CRC of all stages. The Kruskal-Wallis and Spearman correlation tests were used to evaluate associations of patient characteristics with 25(OH)D levels. RESULTS: Median 25(OH)D level at baseline was 27.0 ng/mL (range 7.2, 59.0); 65% of patients had insufficient levels (25(OH)D < 30 ng/mL) (n = 94). Race, disease stage, multivitamin use, vitamin D supplementation, and county of residence were associated with baseline 25(OH)D levels (P < 0.05). The median change in 25(OH)D from baseline to 6 months was - 0.7 ng/mL [- 19.4, 51.7] for patients treated with chemotherapy (n = 58) and 1.6 ng/mL [- 6.4, 33.2] for patients who did not receive chemotherapy (n = 19) (P = 0.26). For patients who received vitamin D supplementation during chemotherapy, the median 25(OH)D change was 8.3 ng/mL [- 7.6, 51.7] versus - 1.6 [- 19.4, 24.3] for chemotherapy patients who did not take vitamin D supplements (P = 0.02). CONCLUSION: Among patients with a new diagnosis of CRC, most patients were found to have 25(OH)D levels consistent with either deficiency or insufficiency. In the subset of patients who received chemotherapy and took a vitamin D supplement, serum 25(OH)D levels increased, suggesting that vitamin D repletion is a feasible intervention during chemotherapy.
Entities:
Keywords:
Chemotherapy; Colorectal cancer; Geographic variation; Supplementation; Vitamin D
Authors: Akiko Chiba; Rachna Raman; Alexandra Thomas; Pierre-Jean Lamy; Marie Viala; Stephane Pouderoux; Sarah L Mott; Mary C Schroeder; Simon Thezenas; William Jacot Journal: Clin Breast Cancer Date: 2017-12-11 Impact factor: 3.225
Authors: W Jacot; N Firmin; L Roca; D Topart; S Gallet; A Durigova; S Mirr; L Abach; S Pouderoux; V D'Hondt; J P Bleuse; P J Lamy; G Romieu Journal: Ann Oncol Date: 2016-03-30 Impact factor: 32.976
Authors: M A Fuchs; C Yuan; K Sato; D Niedzwiecki; X Ye; L B Saltz; R J Mayer; R B Mowat; R Whittom; A Hantel; A Benson; D Atienza; M Messino; H Kindler; A Venook; F Innocenti; R S Warren; M M Bertagnolli; S Ogino; E L Giovannucci; E Horvath; J A Meyerhardt; K Ng Journal: Ann Oncol Date: 2017-06-01 Impact factor: 32.976
Authors: Kimberly A Bertrand; Edward Giovannucci; Yan Liu; Susan Malspeis; A Heather Eliassen; Kana Wu; Michelle D Holmes; Francine Laden; Diane Feskanich Journal: Br J Nutr Date: 2012-01-23 Impact factor: 4.125
Authors: Marissa B Savoie; Alan Paciorek; Li Zhang; Nilli Sommovilla; Alan P Venook; Erin L Van Blarigan; Katherine Van Loon Journal: J Clin Nutr Food Sci Date: 2019-07-12
Authors: Maria Latacz; Jadwiga Snarska; Elżbieta Kostyra; Konrad Wroński; Ewa Fiedorowicz; Huub Savelkoul; Beata Jarmołowska; Janusz Płomiński; Roman Grzybowski; Anna Cieślińska Journal: Nutrients Date: 2020-04-03 Impact factor: 5.717